Anesiva Inc

Anesiva — Algorx Pharmaceuticals — Merger or Acquisition (October 2005)

32 slides from Anesiva's merger presentation, Oct 13, 2005

  1. Slide 1: Creating a Late-Stage Pain and Inflammation Company

    Filed by Corgentech Inc. Pursuant to Rule 425 Under the Securities Act of 1933 And Deemed Filed Pursuant to Rule 14a-12 Under the Securities Exchange Act of 1934 Subject Company: AlgoRx Pharmaceuticals, Inc. Commission File No. of Subject Company: 000-51146 *** *** *** The following is a slide prese

  2. Slide 2: Forward Looking Statements

    FORWARD This “expect,” intended proposed materially merger; segments market contained Corgentech not 2 statement. topresentation place acceptance. approval to merger, grow “estimate,” in from identify and undue LOOKING Corgentech’s as AlgoRx results of includes and anticipated; reliance Actual such

  3. Slide 3: Forward Looking Statements: Additional Information

    FORWARD Additional available documents Investor Corgentech, merger Corgentech Stockholders, 3 above. transaction transaction. Relations because Information filed Inc. described AlgoRx LOOKING which intends with they at involving Information was and the the above. will and to STATEMENTS email their S

  4. Slide 4: Combined Company

    COMBINED Pain Sizable Unmet Faster, 4 Management Cheaper or Patient Underserved COMPANY Populations Trials and Inflammation Medical Needs Differentiated Products with Clear Advantages over Current Therapies Substantial Body of Preclinical and Clinical Data

  5. Slide 5: Creating a Late-Stage Pain Company

    CREATING Four Each discovery Phase Statistically Development Marketing, Financial 5 product drug 3 program strength and has commercialization, significantly LATE-STAGE development and development unique ALGRX commercial andmechanism flexibility less 3268 programs programs COMPANY pain expertise regu

  6. Slide 6: Merger Agreement

    MERGER Stock Corgentech Combined Richard John Dr. James 6 Ronald McLaughlin Transaction Huang Brewer, AGREEMENT management Burch, tonewly issue Dr. as current sufficient elected Charles CEOteam AlgoRx as Cohen, will shares president work CEO, Thomas such towith tothat integrate serve Colligan, respo

  7. Slide 7: Product Pipeline

    PRODUCT Pre-procedural Post-surgical NF- Atopic ALGRX Cutaneous PRECLINICAL PHASE * 7 kBdermatitis Does Decoy 3211207 3268 4975 neuropathic PIPELINE pain not **analgesia reflect (eczema) Morton’s pain comprehensive (003) neuroma Pre-procedural Tendonitis list of trials analgesia currently (004)under

  8. Slide 8: ALGRX 3268 Topical Local Anesthesia

    ALGRX TOPICAL Reduction Indication Two Sterile, Within No 8 vasoconstriction Phase 1pre-filled, 3268- minute of LOCAL 3 trials painwith needle-free associated being ANESTHESIA with duration conducted good with disposable of dermal about venipunctures Keytolerability 10 desirable delivery minutesand

  9. Slide 9: Reduction in Pain Associated with Venipuncture

    Reduction Package EMLA 3 1 Time 60 ALGRX -Data 0 10 VAS, -30 -20 3 5 Time ALGRX 9 mmInsert 10 from after in 3268 after Pain for1from Phase EMLA administration, 3268 trial administration, has an Venipuncture in onset 272 minutes oneafter adults minutes within Administration minute, whereas EMLA is la

  10. Slide 10: ALGRX 3268 Development

    ALGRX Protocol Total Evaluate Pharmacokinetics Lidocaine Primary Achieved Antecubital Children Back 10 2,213 of Hand Endpoint Age 3268 Circulating 3Achieved 574 500 Fossa Group Adults Achieved Children DEVELOPMENT Safety Adults Children andPhase Primary 1and Primary 183 2 1306 145 Efficacy Patients

  11. Slide 11: Phase 3 Identical Protocols

    PHASE IDENTICAL U.S. Design Number 500-600 Pediatric Population Confirm Objectives Primary Assessment 11 multicenter, 3’s: endpoint of subjects efficacy, subjects subjects of 003 PROTOCOLS pain AND randomized, in safety ofon each either 004 venipuncture and study gender tolerability double-blind, (a

  12. Slide 12: Phase 3 Results (003)

    PHASE Primary Statistically 574 ALGRX No Well 12 significant patients tolerated 3endpoint 3268 RESULTS significantly at safety group sixachieved U.S. = issues (003) 289 clinical less (p=0.007) patients pain trialon(ages sites needle 3-18) insertion Placeboin =treated 285 patients group compared (age

  13. Slide 13: Projected Timeline for ALGRX 3268

    PROJECTED Data Clinical Reviewed Regulatory File Registration 13 NDA from in as second 1H06 aTIMELINE drug Phase Product by the 3 trial FOR FDA approval (004) ALGRX Analgesics in expected 1H07 3268 andwithin Acutetwo Caremonths Division

  14. Slide 14: ALGRX 4975 Overview

    ALGRX Capsaicin Administered affect Activates Blocks 14 other noxious 4975 the Overview nerve VR1 locally –pain VR1 fibers channel; with at ANESTHETIC the important long site expressed duration of pain for motor by Single painskills administration receptor C-fibers may provide analgesia for weeks to

  15. Slide 15: ALGRX 4975 Development

    ALGRX Total Protocol 4975 Phase Postsurgical Bunion DEVELOPMENT 2Patients Pain Removal Surgery Primary 22 40 Endpoint Status Hernia Knee Total Repair Cholecystectomy Neuropathic Morton’s 48 2 Magnitude Replacement Pain Neuroma 240 60 Time 182 Magnitude and to Rescue Magnitude ofDuration Dosing Study

  16. Slide 16: Eczema: Common, Chronic Problem

    COMMON, Eczema Red, 90% Affects Very 16 of cracked, common people about (Atopic CHRONIC 15 10-20% and in with Dermatitis) million all unbearably AD parts ofhave PROBLEM people infants of the staph itchy world in the bacteria skin United caused onStates their by excess skin compared inflammation to <

  17. Slide 17: Eczema: Large Unmet Need

    ECZEMA: Unmet Existing Safety Strong Shorter 17 issues preclinical medical time therapies LARGE to with proof need data are long-term UNMET of not with concept satisfactory NF- application NEED kB Decoy (steroids of steroids, showing and calcineurin especially effective treatment in inhibitors) chil

  18. Slide 18: Drug Comparison

    DRUG Topical Twice aCOMPARISON NF- Agents Efficacy Once kB Decoy +++ aday day or+++Steroids ++ Once/twice Calcineurin a day Inhibitors Dosing less thinning Skin- Onset +++ ofShort-term/ Short-term long-term +++None intermittent Limits ++effects use None action Systemic Limited exposure Rebound 18 Ma

  19. Slide 19: NF-kB Decoy for Eczema

    NF-kB Two Safety, Multiple Physician US Four 0.25% Trial 0.50% 1.00%Phase cohorts Placebo 21 days Ex-US Three days 1.0% tolerability DECOY (75 endpoints 20and 151/2 patients) patient trials 40FOR patients cohorts Trial daily of 2x and tounderway patients treatment (120 day40 assessments assess ECZEM

  20. Slide 20: ALGRX 1207

    ALGRX IND-enabling New Deep, Neuropathic 20 chemical rapid 1207 penetration pain studies class Dermatological ofunderway local of theanesthetic skinsurgery and for long Surgical topical duration analgesia incisions of action Addresses a wide variety of procedures including:

  21. Slide 21: New Local Anesthetic ALGRX 1207

    New80 Percent 100 -120 Time, ALGRX Lidocaine Unique 21 -110 -60 local minutes 60 non-clinical complete 01207 -100 40 anesthetic 60 20 120 -90 0anesthesia 180 results allowing 240 300 in relevant rapid 360 420 andmodels complete topical anesthesia without exotic delivery

  22. Slide 22: Prevalence of Pain in Seven Major Countries

    PREVALANCE PATIENT Prevalence Above Source: 22 indications Datamonitor NUMBERS of osteoarthritic post-operative back HIV diabetic OFare and pain PAIN all neuropathy AIDS 208,996,000 targets INpain pain pain SEVEN of 46,610,000 75,068,000 pain 847,000 Corgentech MAJOR 13,243,000 pipeline COUNTRIES

  23. Slide 23: 3268: Topical Anesthesia Market Dynamics

    3268: TOPICAL ANESTHESIA Strong pressure Current 23 focus market on cost of dynamics MARKET pain reduction LOCAL management provide and DYNAMICS patient an including excellent through-put treatment opportunity in hospitals protocols for aFundamental and fast guidelines acting, easy market Increase t

  24. Slide 24: Underserved Target Market

    UNDERSERVED Target Only Low Faster 24 utilization 2.1MM onset marketofout action, ofoftopical MARKET 18MM needleless local venipuncture anesthetics injectionprocedures and (12%promotion of pediatric in children’s willprocedures) allow hospitals significant dueand to large penetration slow academic o

  25. Slide 25: 3268: Phased Marketing Approach

    3268: PHASED Physician Hemodialysis In-hospital 25 18M Offices, Adult Pediatric Centers MARKETING (ER) Labs, Blood Donation APPROACH Centers

  26. Slide 26: US Post-Operative Pain Market

    ALGRX US 50% Pain 26 post-operative in indicate hospital 4975:lack POST-OPERATIVE associated of pain adequate market: withpain $1.7 increased control PAIN billion length MARKET Patients’ Virtually of stay, post-surgical all patients longer recovery experience pain experiences times, somepoorer level

  27. Slide 27: Current Post-Op Pain Medications vs. ALGRX 4975

    CURRENT Use Epidurals Nausea, Opioids Decreased Concern Unacceptable Non-narcotics ALGRX Unlikely addiction 27 declining vomiting, about 4975 to potential bowel be POST-OP anesthesia significantly contra-indicated addiction function respiratory Long-acting PAIN for leads can due moderate MEDICATIONS

  28. Slide 28: Eczema Market

    NF-kB Eczema Patient Severe Moderate 31.1M 5.2M 15.6M Mild 1. Sources: 2. 28 International Prevalence 60% 10% Population DECOY: market 30%ofConsensus isAtopic ECZEMA comprised Segmented Dermatitis Conference MARKET ofbymild, Mild, in Japanese moderate on Moderate Atopic Adults, and Dermatitis and se

  29. Slide 29: NF-kB Decoy: Total Corticosteroid Rx Sales

    NF-kB Total 1999 Corticosteroids Source: 29 2000 Dollars DECOY: IMS2001 Health, (millions) Protopic 2002 Rx SALES 2004 2003 $900 Elidel 2004 (U.S.) $800 $700 $600 $500 $400 $300 $200 $100 $0

  30. Slide 30: ALGRX 1207: Target Market

    ALGRX1207: Deep, Lidoderm® ($ 2001 30 in millions) 2002 rapid2003 penetration (Endo TARGET $45 2004E Pharmaceuticals) $1072005E of $215 MARKET the skin $300 (IMS) Long $400 Postherpetic (IMS) duration (IMS)Neuralgia of(Endo) action(Endo) Addresses Indicationneuropathic pain market Non-exotic deliver

  31. Slide 31: Deal Timeline

    DEAL Both Merger S-4 Shareholder 31 and boards TIMELINE requires documents related vote have joint stockholder expected approved toProxy be filed to Statement merger approval occur shortlyin late 2005 / early 2006

  32. Slide 32: Why This Merger Makes Sense

    WHYproduct Four Each discovery Phase Statistically Development Marketing, Financial 32 drug THIS 3 program strength and has commercialization, significantly MERGER development and development unique ALGRX commercial andmechanism flexibility MAKES less 3268 programs programs pain expertise regulatory

Algorx Pharmaceuticals — Merger or Acquisition (October 2005) on 6ix